Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial)

Ruoyang Li,1 Meiqi Wang,1 Xiangshun Kong,2 Jie Ma,3 Xiuheng Qi,4 Zhenchuan Song1 1Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department of Breast Surgery, Xingtai People’s Hospital, Xingtai, People’s Republic of China; 3Department of Breast...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Li R, Wang M, Kong X, Ma J, Qi X, Song Z
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Dove Medical Press 2025-09-01
Saila:	Drug Design, Development and Therapy
Gaiak:	Breast cancer Human epidermal growth factor receptor 2 Trastuzumab-resistant Pyrotinib Eribulin
Sarrera elektronikoa:	https://www.dovepress.com/eribulin-plus-pyrotinib-in-trastuzumab-resistant-her2-positive-advance-peer-reviewed-fulltext-article-DDDT
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!